Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 5Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Dwarfism, Pituitary 1Bone Diseases, Metabolic 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × Risedronic Acid × Clear all
NCT00216060 2016-05-26

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Hoosier Cancer Research Network

Phase 3 Terminated
63 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT00145704 2013-04-08

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

State University of New York - Upstate Medical University

Phase NA Terminated
6 enrolled 3 charts
Endocrine

Bone Diseases, Metabolic, Dwarfism, Pituitary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡